CMS/FDA Parallel Review: Agencies Weighing Process For Planning Trials That Satisfy Both
Executive Summary
CMS and FDA are considering a voluntary process that would help drug, biologic and medical device sponsors design clinical trials that would ultimately support both FDA approval and CMS national coverage decisions for Medicare reimbursement.
You may also be interested in...
Medicare CED Could Enable Expanded Use Of Expedited Drug Approvals, Policy Groups Suggest
Based on stakeholder consultations, former FDA and CMS head Mark McClellan and former CMS official Sean Tunis present a potential upside for biopharma in broader use of Medicare coverage with evidence development. Pfizer executives participate in workshop on coordinating expedited drug approval, CED policies.
IPAB Will Make CMS More Relevant In Parallel Reviews With FDA, Former Official Gottlieb Predicts
BALTIMORE – Decisions by the soon-to-be-created Independent Payment Advisory Board could make CMS participation in parallel review of drugs with FDA much more meaningful than it would otherwise be, assuming the health care reform law remains intact, former CMS and FDA official Scott Gottlieb said.
IPAB Will Make CMS More Relevant In Parallel Reviews With FDA, Former Official Gottlieb Predicts
BALTIMORE – Decisions by the soon-to-be-created Independent Payment Advisory Board could make CMS participation in parallel review of drugs with FDA much more meaningful than it would otherwise be, assuming the health care reform law remains intact, former CMS and FDA official Scott Gottlieb said.